German drugmaker Merck KGaA has begun the second year of its five-year project to provide diabetes management courses for medical and pharmacy students in African Universities.
German drugmaker Merck KGaA has begun the second year of its five-year project to provide diabetes management courses for medical and pharmacy students in African Universities.
The Merck Capacity Advancement Program (CAP) will be provided at the Universities of Nairobi, Makerere, Uganda, and Namibia, before moving to Tanzania and Ghana. Merck is also offering every healthcare provider in those countries and the rest of Africa free access to the lectures via e-learning at www.managediabetesonline.org.
This year the company aims to reach 2,000 students and rural healthcare providers, who will have the opportunity to become “diabetes ambassadors” across Africa.
Merck’s Dr. Stefan Oschmann and Professor Sidat Mohsin, dean of the medical school at Eduardo Mondelane University, Mozambique.
The challenges faced by African countries in tackling diabetes are well known: services for the care of chronic diseases are poorly organized; public awareness about diabetes is limited, and well-structured education programs for patients and health professionals are unavailable.
According to the International Diabetes Federation, the number of people with diabetes in Africa could double by 2035. The proportion of deaths due to diabetes in people under 60 years in Africa is currently 76%, and 46% of people living with diabetes are still undiagnosed.
Next year Merck’s program will be extended to more universities across Africa such as Nigeria and Ethiopia, and to Asian countries such as Indonesia and India.
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
Talphera Cuts NEPHRO CRRT Study Size, Secures $14.8 Million Private Placement
April 1st 2025The trial size adjustment, along with protocol modifications and the addition of higher-enrollment sites, is expected to facilitate completion of the NEPHRO CRRT study of Niyad in patients undergoing renal replacement therapy by the end of 2025.